CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BIONET Therapeutics Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BIONET Therapeutics Corp
No.28
Lane 36, Xinhu 1st Road, Neihu District
Phone: +886 800800018p:+886 800800018 TAIPEI, 114  Taiwan Ticker: 78087808

Business Summary
BIONET Therapeutics Corp is a Taiwan-based company primarily engaged in the development, manufacture and provision of advanced therapies such as regenerative medical preparations and cell therapy preparations. The Company focuses on regenerative medical preparations, cell preparations, smart research and development, smart health, exosomes, gene and cell therapy. The Company has 7 cell therapy preparations in development, including acute respiratory distress syndrome (ARDS) (human clinical phase 2), pulmonary fibrosis (clinical phase 2), chronic renal failure, acute wound healing, and chronic wound healing for diabetic ulcers, degenerative arthritis, dry eye. The Company has used exosomes for commercial production of skin care products.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202412/31/2023-----

General Information
Number of Employees: 24 (As of 12/31/2023)
Outstanding Shares: 70,000,000 (As of 12/12/2024)
Stock Exchange: TPO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 22, 2024